Gastrointestinal cancers, ACE-2/TMPRSS2 expression and susceptibility to COVID-19

Cancer Cell Int. 2021 Aug 16;21(1):431. doi: 10.1186/s12935-021-02129-x.

Abstract

Recent studies on the pathophysiology of COVID-19 are indicating that the Angiotensin convertase enzyme 2 (ACE-2) and transmembrane serine protease 2 (TMPRSS2) can act as a major component in the fusion of SARS-Cov-2 with target cells. It has also been observed that the expression of ACE-2 and TMPRSS2 can be altered in malignancies. Shedding light on this matter could be crucial since the COVID-19 pandemic interfered with many gastrointestinal cancer screening programs. Herein we discuss the possibility of severe forms of COVID-19 in patients with gastrointestinal cancers due to the gastrointestinal entry route of SARS-CoV-2 into the human body. The disruption of cancer screening programs caused by the current COVID-19 pandemic could therefore have massive negative health impact on patients affected by gastrointestinal malignancies.

Keywords: Angiotensin convertase enzyme 2; COVID-19; Gastrointestinal cancer; Pathophysiology; transmembrane serine protease 2.

Publication types

  • Review